About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00862992

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be admini...

Lead sponsor: Tanabe Pharma Corporation•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Tanabe Pharma Corporation

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients meeting DSM-IV-TR criteria for schizophrenia
•PANSS total score \<= 120 during the observation period
•Patients who have been treated with oral antipsychotics within 4 weeks before informed consent
•Patients whose consent is obtained from themselves in written form

Exclusion Criteria

•Patients who have defined as any mental disorder other than "Schizophrenia" based on the criteria of DSM-IV-TR
•History of drug or alcohol abuse
•Concurrent Parkinson's disease
•History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease, anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic disorder
•Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, ECG, or clinical laboratory values
•Current cataract during the observation period
•History of shock or anaphylactoid symptoms to drugs
•The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related studies

RECRUITINGPhase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · Schizophrenia

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · Schizophrenia

RECRUITINGPhase 2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853 · Prodromal Schizophrenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 5, 2026Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment34

Start dateApr 2008

Last updatedJan 5, 2026

Condition

Locations shown

Hoyu Hospital

Kure, Hiroshima

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions